Tandem Diabetes Care Announces Second Quarter 2020 Financial Results and Full Year 2020 Sales Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Tandem Diabetes (TNDM) Misses Q2 EPS by 21c, Revenues Beat; Offers FY20 Revenue Guidance Above Consensus, 3Q Revenues Outlook Below Consensus
July 30, 2020 4:21 PM EDTTandem Diabetes (NASDAQ: TNDM) reported Q2 EPS of ($0.45), $0.21 worse than the analyst estimate of ($0.24). Revenue for the quarter came in at $109.2 million versus the consensus estimate of $87.15 million.
We achieved our highest quarterly sales, successfully completed our first acquisition, and executed multiple meaningful agreements in support of our longer-term objectives in the second quarter, said John Sheridan,... More
